AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Position Lifted by Barclays PLC

Barclays PLC boosted its holdings in AbCellera Biologics Inc. (NASDAQ:ABCL) by 72.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 38,351 shares of the company’s stock after acquiring an additional 16,058 shares during the period. Barclays PLC’s holdings in AbCellera Biologics were worth $112,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ABCL. Guardian Partners Inc. acquired a new position in AbCellera Biologics during the 4th quarter worth $5,413,000. Norges Bank bought a new stake in shares of AbCellera Biologics during the 4th quarter worth $3,764,000. ExodusPoint Capital Management LP acquired a new stake in AbCellera Biologics during the 4th quarter worth about $826,000. DnB Asset Management AS boosted its stake in AbCellera Biologics by 424.7% in the 4th quarter. DnB Asset Management AS now owns 305,579 shares of the company’s stock worth $895,000 after purchasing an additional 247,342 shares during the period. Finally, Moloney Securities Asset Management LLC acquired a new position in AbCellera Biologics during the fourth quarter valued at $265,000. 61.42% of the stock is currently owned by institutional investors.

AbCellera Biologics Stock Performance

Shares of NASDAQ ABCL opened at $2.05 on Thursday. AbCellera Biologics Inc. has a 52-week low of $1.89 and a 52-week high of $4.34. The stock has a market cap of $611.77 million, a PE ratio of -3.36 and a beta of 0.46. The business has a fifty day moving average of $2.31 and a two-hundred day moving average of $2.73.

AbCellera Biologics (NASDAQ:ABCL) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.02. AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%. The business had revenue of $4.24 million for the quarter, compared to the consensus estimate of $7.12 million. Analysts predict that AbCellera Biologics Inc. will post -0.59 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ABCL shares. Benchmark reiterated a “hold” rating on shares of AbCellera Biologics in a report on Monday, March 3rd. KeyCorp increased their price objective on AbCellera Biologics from $4.00 to $5.00 and gave the company an “overweight” rating in a research report on Wednesday, April 16th. Finally, Stifel Nicolaus reduced their price objective on AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, February 28th.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.